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ABSTRACT 
 
Transport and Utilization of Arginine and Arginine-
Containing Peptides by Rat Alveolar Macrophages 
 
Xiaodong Yang 
 
Purpose. To demonstrate that alveolar macrophages (AM) from 
rats exhibit pepT1-like transporter for the uptake of small 
arginine-containing peptides (ACPs) and utilized these 
peptides as direct substrates for nitric oxide (NO) 
production.  
 
Method. A HPLC assay was developed for quantitative 
measurement of Arg and ACPs in rat plasma and 
bronchoalveolar lavage (BAL) fluid. The uptake of small 
peptides by rat AM was evaluated using fluorescein 
isothiocynate (FITC)-labeled (*) peptides (Arg-Lys*, β-Ala-
Lys*, and Gly-Sar-Lys*), HPLC analysis of potential peptide 
degradation, and known inhibitors on arginine (Arg) and 
PepT1 transport. NO production by AM through Arg and ACPs 
was studied with and without inhibition by transport 
inhibitors. The presence of PepT1-like transporter on AM 
was evaluated using antipepT1 antisera and Western blot 
analysis. The substrate specificity of Arg-Gly and Arg-Gly-
Asp was determined using purified inducible nitric oxide 
synthase (iNOS). The availability of ACPs in the lung was 
determined by the HPLC analysis of plasma and (BAL) fluid. 
 
Results. The FITC-labeled peptides were internalized by AM 
without degradation. Uptake of Arg-Lys*, β-Ala-Lys*, and 
Gly-Sar* was blocked (~50%) by cephradine, but not by Lys 
(an inhibitor on CAT-2B for arginine transport). The NO 
production by AM through ACPs was significantly blocked by 
PepT1 inhibitors and by an antiPepT1 antibody in a dose-
dependent manner. These inhibitors had no effect on AM 
production of NO using Arg as a substrate. Arg-Gly and Arg-
Gly-Asp were found to be direct substrates for iNOS with 
similar Km and Vmax values to those of Arg. But the 
production of NO by AM using ACPs as substrate was 2-fold 
higher than using Arg as a substrate. Both Arg-Gly and Arg-
Gly-Asp were found in rat plasma and BAL fluid. The 
presence of a PepT1-like transporter on AM was confirmed by 
Western blot. 
 Conclusion. This study shows that AM exhibits PepT1-like 
transporter for small peptide uptake. ACPs, through PepT1-
like transporter, can serve as direct substrates for AM 
production of NO, an important mediator on both protection 
the lung from bacteria infection and augments inflammation 
lung injury. 
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Chapter I 
 
Statement of Question, Hypothesis, and Specific Aims of This 
Study 
 
Peptide transporters play a pivotal role in efficient 
absorption of protein digestion products (mainly di- or 
tri-peptides) through plasma membranes in the small 
intestine.  As a result of the transport of these small 
peptides, up to 78% of the amino acids in the plasma are in 
the form of di- or tri-peptide in experimental animals 
(Seal and Parker 1991).  Removal of such large amounts of 
small peptides from the plasma into an organ could be the 
result of dipeptide hydrolysis in plasma or of actual 
utilization of peptides by the organ.  Lochs et al. (1988) 
showed that the hydrolysis in plasma was not a major 
mechanism for the disappearance of dipeptides from 
circulation.  This suggests that direct utilization of 
these peptides could occur in various tissues.   
 
Indeed, direct utilization of small peptides by 
different tissues has been reported (Krzysik and Adibi, 
1977; McCormick and Webb, 1982).  Fei et al. (1994) 
reported that small peptides might be directly used by the 
liver, kidney, brain and placenta.  More recently, Wang et 
al (1996), for example, reported that di- or tri-
methionine-containing peptides were more efficiently 
utilized than free methionine in the synthesis of mammary 
tissue proteins secreted from lactating mice.  The 
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utilization of small peptides in anabolic process in other 
tissues, including the lung remains unclear. 
 
In pulmonary host defense, nitric oxide (NO) is 
produced in particularly large amounts by alveolar 
macrophages (AM) to provide cytostatic/cytotoxic effects 
against invading bacteria.  Induction of NO production by 
AM and agents such as lipopolysaccharide (LPS), depends not 
only on the activity of the inducible nitric oxide synthase 
(iNOS), but also on the availability of the substrate 
arginine.  Recent studies have shown that arginine is taken 
up by AM through the cationic amino acid transporter 2B 
(CAT-2B) (Caivano, 1998).  LPS, which stimulates the 
production of iNOS, also facilitates AM uptake of arginine 
(Kakuda et al., 1999).   
 
The substrate for NO synthesis may not be necessarily 
restricted to arginine.  Thiemermann et al. (1991) reported 
that in endothelial cells, arginine-containing dipeptides 
fit the active site of NO synthase than arginine in 
endothelial cells.  In addition, Meredith and Boyd (1995) 
reported the presence of a peptide transport protein in the 
pulmonary type II cells and suggested that this transporter 
may play a role in lung peptide homeostasis.  Recently 
Groneberg et al. (2001) demonstrated the presence of a 
peptide transporter in alveolar type II pneumocytes, 
bronchial epithelium, and endothelium of small vessels of 
mammalian lungs.  Due to the availability of small peptides 
in plasma and the presence of peptide transporter in the 
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alveolar epithelium and endothelium, direct utilization of 
these small peptides is therefore feasible. 
 
The hypothesis of this study was that alveolar 
macrophages can take up arginine-containing peptides and 
directly utilize them as substrates for NO production, and 
that this process is regulated by a peptide transporter. 
 
A number of transporters including PepT1 and PepT2 
located in the intestinal and kidney epithelial cells, 
respectively, have been identified for di- or tri-peptide 
transport (Fei et al., 1994, Saito et al. 1996).  It is 
reasonable to suggest that in various organ systems, where 
transport or absorption of small peptide is necessary, 
there are similar peptide transporters. 
 
In order to characterize the potential presence of a 
peptide transporter on AM, this research used the structure 
of PepT1 (Figure 1) as a model to test the underlying 
hypothesis.  In this approach, two peptide segments, 
peptide I and peptide II (figure 1-3), while exhibit high 
homology in amino acid sequence among rat, rabbit, and 
human PepT1, were chosen to produce the anti-PepT1 
antisera, and used as proteins for the detection of a 
peptide transporter on AM. 
 
The specific aims of this study were: 
(1) To develop a reliable method for the analysis of 
arginine and arginine-containing peptides in the 
biological system, 
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(2) To establish that appreciable amount of arginine-
containing small peptides are present in the lungs  
(3) To demonstrate the presence of a peptide transporter 
in alveolar macrophages (AM) and the uptake of 
arginine-containing peptides through this transporter, 
and 
(4) To determine the arginine-containing peptides are 
direct substrates for the inducible nitric oxide 
synthase (iNOS) in AM for NO production. 
 
The outcome of this research should provide a 
plausible mechanism for the role of arginine-containing 
peptides in vivo NO production. 
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Chapter II 
 
Review of Literature 
 
1. Peptide Transporters 
 
The existence of a peptide transporter in human small 
intestine was hypothesized more than 25 years ago (Matthews 
and Adibi, 1976).  Due to the technical difficulty, this 
transporter protein was not identified until recent years.  
The first peptide transporter, called (PepT1) was cloned by 
Fei et al. (1994) from rabbit small intestine.  The second 
one, called PepT2, was cloned from absorptive cells of the 
renal proximal tubule (Saito et al., 1996).  The discovery 
of peptide transporters not only supported the hypothesis 
but also provided a useful tool for studying the 
utilization of peptides by various tissues. 
 
1.1. Physiological Importance 
 
1.1.1. Peptide Transporter in the Small Intestine  
 
The physiological importance of a small peptide 
transporter became apparent with the observation of small 
peptides in the gut lumen, then their disappearance from 
small intestine, and reappearance in portal vein after a 
protein meal.  Adibi et al. (1971 and 1981) investigated 
whether intact absorption played a role in the small 
peptide disappearance.  A series of small peptides were 
infused directly into the upper small intestine of human 
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volunteers and their fates were determined.  The results of 
these studies suggested the absorption of large amount 
dipeptides and tripeptides in an intact form.   
 
This observation challenged the traditional idea that 
dietary proteins must be broken down to amino acids in the 
gut lumen before absorption could occur.  The importance of 
peptide transporter was further confirmed by the fact of 
patients with genetic impairments of amino acid absorption 
(Cystinuria and Hartnup diseases).  These impaired 
individuals do not experience protein malnutrition.  
 
Cystinuria patients lack the basic amino acid 
transporter and can not absorb arginine from their 
intestine.  However, the dipeptide Arg-Leu is well absorbed 
in these patients.  Hartnup disease is a hereditary 
condition in which the active transport of several neutral 
amino aids is deficient from both renal tubules and the 
small intestine.  It exhibits a pellagra-like syndrome, but 
is benign, and patients fare quite well nutritionally by 
absorbing small peptides.  This would not have been 
expected if the amino acid transporters, instead of the 
peptide transporters, were mainly responsible for 
absorption of protein digestion products. 
 
1.1.2. Peptide Transporter in Kidney 
 
In addition to the PepT1 in small intestine, a peptide 
transporter (PepT2), is also present in absorptive cells of 
the renal proximal tubule (Saito et al., 1996).  This 
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transporter via the active transport process plays a 
significant role in conserving peptide bound amino nitrogen 
which might otherwise be lost in the urine.   
 
Such a physiologically significant role, however, was 
not readily accepted because it was generally assumed that 
the concentrations of small peptides in the circulation 
were very low.  However, recent studies (Gardner, 1994, 
Matthews 1994, Schlagheck and Webb, 1984, Seal and Parker, 
1991) have provided clear evidence that up to 70% of the 
plasma amino acid pool is in the peptide-bound form.  
 
1.2. Regulation of Peptide Transporter 
 
The knowledge on the regulation of peptide 
transporters is limited.  The ability of the intestine to 
absorb intact peptides varies with age.  In several animal 
species including man, the peptide transport system is 
established in the small intestine prior to birth 
(Guandalini and Rubino, 1982, Himukai et al., 1980, Sagawa 
et al., 1979).  The peptide absorptive capacity is maximal 
at birth and then decreases with age to reach adult levels.  
 
The intestinal peptide transport system is also 
regulated by diet. A high-protein diet enhances the ability 
of the intestine to absorb peptides. A switch from a low- 
to a high-protein diet resulted in a 1.5-2 fold increase in 
the pepT1 mRNA level in rat intestine (Ferraris et al., 
1988).  Vazquez et al. (1985) showed that metabolic 
perturbations, such as starvation, alter peptide transport 
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in the jejunum of human volunteers. Short-term restriction 
of diet, for example, increases the intestinal peptide 
transport activity.  However, the mechanism that might 
regulate this transporter was not studied. 
 
Our present knowledge of the regulation of the 
intestinal peptide transport system by hormones is limited.  
Little is known about the regulation of the peptide 
transport in the kidney.  The principal peptide transporter 
expressed in the kidney through the action of hormones 
and/or second messengers has not been studied. 
 
1.3. Therapeutic Application 
 
1.3.1. Pharmacological Importance 
 
The peptide transport systems present in the small 
intestine and the kidney also have pharmacological 
relevance.  Many orally active peptide-like drugs possess 
structural features similar to those of the physiologic 
substrates of the peptide transport system.  The intestinal 
peptide transport system recognizes these peptide-like 
drugs (e.g. β-lactam antibiotics) as substrates and acts as 
a vehicle for their effective absorption (Okano et al., 
1986).   
 
The peptide transport system in the kidney is 
responsible for active reabsorption of these antibiotics 
from the glomerular filtrate and, hence, increases their 
half-life in the circulation.  Thus, the intestinal and 
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renal peptide transport systems play an important 
pharmacologic role in determining the efficiency of these 
antibiotics.   
 
It is obvious that the peptide antibiotics are not the 
only pharmacologically relevant compounds that use the 
peptide transport system as a vehicle for cellular uptake.  
The transport system also participates in the transport of 
many other therapeutically and biologically active 
peptides, such as angiotensin-converting enzyme inhibitors, 
renin inhibitors, and anticancer drugs (Inui et al., 1992).   
 
1.3.2. Clinical Importance 
 
The peptide transport system in the small intestine 
and the kidney has received increasing attention in recent 
years.  In current clinical practice, short-chain peptides 
are being seriously considered as viable substitutes for 
free amino acids in enteral and parenteral solutions.  The 
reason for that is that since the transport of peptides in 
the small intestine is the primary mode of nitrogen 
absorption, it is logical to employ all peptides instead of 
free amino acids as the source of nitrogen in enteral 
solutions for patients.   
 
Available evidence in laboratory animals and in man 
strongly suggests that enteral solutions containing small 
peptides may provide an absorptive advantage to patients 
with severely reduced intestinal absorptive area and to 
patients who are acutely cachectic (trauma, sepsis, and 
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burns).  Moreover, synthetic di- and tri-peptides offer an 
effective alternative means of amino acid delivery using 
enteral solutions for those amino acids that are unstable 
or sparingly soluble in free form (e.g. tyrosine, cystine, 
glutamine). 
 
Expanded knowledge about extraintestinal peptide 
assimilation in animals, especially the extraordinary 
ability of the mammalian kidney to extract small peptides, 
is supporting the view that small peptides can be 
substitute for free amino acids, not only in enteral 
solutions, but also in parenteral solutions.  Recent 
studies have shown that it is possible to supply daily 
nitrogen requirements, intravenously, in the form of small 
peptides to animals and man (Grimble et al., 1988, 
Steinhardt et al., 1984).   
 
The low osmolality of peptide-based parenteral 
solutions is another advantage, especially in patients with 
severe fluid restriction.  Furthermore, some free amino 
acids, e.g. glutamine, are relatively unstable in solution 
and during heat sterilization.  However, when included in 
the form of a dipeptide, alanyl-glutamine (Ala-Gln), for 
intravenous solutions, unlike free glutamine, is stable.  
Human studies have shown that utilization of alanyl-
glutamine is highly efficient and that the supplementation 
of the parenteral solutions with this peptide significantly 
reduces postoperative nitrogen losses and prevents the 
post-operative reduction in muscle glutamine content 
(Stehle et al., 1989).   
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Thus, the peptide-based parenteral solutions may offer 
a variety of advantages in a clinical setting, and the 
basis for the clinical efficacy of these solutions is the 
ability of extraintestinal tissues, primarily the kidneys, 
to utilize peptides via the peptide transport. 
 
In addition, the water solubility of some amino acids, 
particularly tyrosine, is limited.  Water solubility of 
tyrosine can be greatly increased by attachment of this 
amino acid to a water-soluble amino acid in dipeptide form.   
Therefore, mixtures of small peptides are used widely as 
the nitrogen source for nutrition. 
 
1.4. Tissue Distribution, Amino Acid Sequence, Antibody to 
Peptide Transporters 
 
PepT1 is expressed predominantly in epithelial cells 
of the small intestine.  Rat PepT1 is a 710 amino acid 
protein (rat) and is a highly conserved between species, 
77% and 83%, with that of rabbit and human, respectively 
(Miyamoto et al., 1996).  mRNA of PepT1 has been found in 
other tissues including kidney, liver, brain, and pancreas 
(Fei et al., 1994; Liang et al., 1995). 
 
PepT2 is expressed predominantly in the kidney, and to 
a small extent in the central nerve system and spleen.  It 
is a 729 amino acid protein and showed 60-80%, and 83% 
amino acid sequence identity with that of rabbit and human, 
respectively.   
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Both PepT1 and PepT2 share three common structural 
features: (1) twelve α-helical transmembrane domains; (2) 
one large extracellular loop that is positioned between 
transmembrane domain 9 and 10; (3) intracellular location 
of both N- and C- terminus amino acid.  Overall amino acid 
identity is 48% between PepT1 and PepT2 in the rat.  
Giacomini (1999) suggested that the extracellular loop 
might play an important role in the interaction between 
substrates and transporter. 
 
Anti-peptide antibodies to transporters have been used 
to identify and localize transporter protein (Saito et al., 
1995; Sai et al., 1996).  These anti-PepT1 antibodies 
against synthetic peptides corresponding to the C-terminal 
13-15 amino acids of the transporter were used in 
immunoblotting and immunohistochemistry studies.   
 
1.5. Peptide Transporter in Lung 
 
The evidences for the presence of a peptide 
transporter in lungs have increased.  Morimoto et al. 
(1993) reported that dipeptides could be transported across 
the alveolar epithelial cell monolayers.  Transport of 
tripeptides in the lung has been investigated in detail 
(Helliwell et al., 1994).  Meredith and Boyd (1995) 
suggested that a proton-coupled peptide transport protein 
is present in the apical surface of the pulmonary type II 
cells, and that this transporter may play a role in lung 
peptide homeostasis. 
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Recently, a peptide transporter was reported to be 
present in mammal lung cells, including alveolar type II 
pneumocytes, bronchial epithelium, and endothelium of small 
vessels (Groneberg et al., 2001).  The presence of the 
peptide transporter in various cell types suggested that 
direct utilization of peptides could occur also in the 
lung. 
 
2. Arginine and Arginine-Containing Peptides in Plasma and 
Bronchoalveolar Lavage (BAL) Fluid  
 
In our classical understanding of protein absorption, 
we believe that dietary proteins are completely hydrolyzed 
to free amino acids in the gut and that only free amino 
acids can be transported by intestinal mucosa into the 
circulation.  There is now substantial evidence that this 
concept is not valid.  In fact, after a protein meal, most 
amino acid constituents of proteins are not absorbed as 
free amino acids but as dipeptides and tripeptides (Adibi 
and Kim, 1981).   
 
Webb (1986) reported that when comparing the 
appearance of amino acids in portal plasma after a meal, 
more than 70% were associated with the peptide amino acid 
in experimental calves.  If these peptide amino acids are 
of dietary origin, then this large contribution will be 
significant.  Even if these peptide amino acids are not of 
dietary protein origin, they present a large quantity of 
amino acids with which other tissues in the animal must 
  Chapter II Review of Literature 
 14 
deal.  There is excellent agreement between Seal and Parker 
(1991) and Gardner (1982, 1983) who reported that about 50% 
peptide amino acids in rat and 65-78% in steer and sheep.   
 
The distribution of the free amino acids arginine in 
rat plasma and tissues has been reported (Barbul, 1990).  
The concentration of arginine is 79-124 µM in plasma and 
0.03-0.28 µmol/g in different tissues.  However, no 
information is available about the distribution of 
arginine-containing di- or tri-peptides in plasma and BAL 
fluid. 
 
3. Nitric Oxide, Arginine, and Arginine-Containing Peptides 
 
Nitric oxide (NO) is an important signal transduction 
mediator in a variety of physiological systems (reviewed in 
Schmidt and Walter, 1994).  In pulmonary host defense, NO 
is produced by alveolar macrophages (AM) in response to 
inflammatory stimulation to provide cytotoxic effects 
against invading bacteria (Beckerman et al. 1993), or to 
regulate cellular cytokine secretion and cyclooxygenase 
activity (Raso et al. 2001).  The induction of NO 
production from AM, such as by lipopolysaccharide endotoxin 
(LPS), depends not only on the activity of the inducible 
nitric oxide synthase (iNOS), but also on the availability 
of the substrate arginine.   
 
NO synthesis from arginine is a reaction, which 
involves two separate mono-oxygenation steps (Stuehr et 
al., 1991).  Nω-Hydroxyarginine is an intermediate species 
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formed by a reaction requiring one O2 and one NADPH and the 
presence of tetrahydrobiopterin (BH4).  This reaction 
appears to be similar to those carried out by the aromatic 
amino acid hydroxylases, which also require BH4.  The second 
step in the NO synthase reaction results in the oxidation 
of Nω-Hydroxyarginine to form citrulline and NO.  Briefly 
the production of NO can be described by following 
formulae: 
 
Arg + NADPH + H+ + O2 → HydroxyArg + NADP+ + H2O 
HydroxyArg + 1/2 (NADPH + H2) + O2 → Cit + NO + H2O 
 
Arginine as substrate for NO production has been 
studied in detail (Barbul, 1990).  However, little is known 
whether or not arginine is the only substrate.  Thiemermann 
et al. (1991) showed that Arg-Phe fits the active site of 
endothelial cell NOS than arginine and that this peptide is 
not degraded to free amino acid during the reaction.  This 
suggested that the substrate specificity of the NOS in 
endothelial cells is not necessarily restricted to L-Arg.   
 
4. Uptake of Arginine, Arginine-Containing Peptides by 
Alveolar Macrophages for NO Production 
 
System y+ is widely believed to be the major carrier of 
cationic amino acids in adult tissues (Malandro and 
killberg, 1996).  Arginine is transported across cell 
membranes by system y+ which is Na+ independent and pH 
insensitive (White et al., 1982). 
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Three cationic amino acid transporters have been 
identified termed CAT-1, CAT-2, and CAT-2B.  CAT-1 and CAT-
2B are present in macrophages and monocytes.  In RAW264 
macrophages, CAT-1 is accounted for the basal rate of 
arginine uptake, while CAT-2B, induced by the 
lipopolysaccharide (LPS), a component of the bacterial cell 
wall, is responsible for the increased rate of arginine 
uptake.  The uptake of arginine can be competitively 
blocked by cationic amino acid e.g. lysine (Bogle et al. 
1992).   
 
The importance of CAT transporters and arginine uptake 
for the production of NO in AM is well documented, however, 
whether arginine-containing peptides can be taken up as 
direct substrates for NO production remains to be 
determined.   
 
5. Nitric Oxide Synthases (NOS) 
 
Nitric oxide is produced from arginine by nitric oxide 
synthase (NOS).  NOS was first described in 1989 (Knowles 
et al., 1989), first purified in 1990 (Bredt and Snyder, 
1990), and first cloned in 1991 (Bredt et al., 1991).  
There are three NOS isoforms have been identified in 
mammalian cells to date.  Type I NOS (nNOS, originally 
identified as a constitutive protein in neuronal tissue) 
and type III NOS (eNOS, originally identified as 
constitutive in vascular endothelial cells) are calcium-
dependent enzymes that are expressed in a cell-specific 
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manner and their activation produces the NO that mediates 
most of the cGMP messenger functions of this molecule.  In 
contrast, type II NOS (iNOS, originally identified as being 
inducible by cytokines in macrophages and hepatocytes) has 
an ubiquitous tissue distribution and is only expressed 
during cell-mediated immune responses.  For this reason it 
is usually referred to as inducible NOS (iNOS).  The iNOS 
in macrophages is only found to be expressed after 
induction with LPS or cytokines.  The half-saturating 
concentration (Km) of the substrate L-arginine measured in 
vitro for iNOS is about 30 µM (Closs et al., 2000).   
 
6. Measurement of NO 
 
In general,  two techniques have been commonly used as 
the basis for the measurement of NO, the oxidation of 
hemoglobin and the formation of NO2- + NO3-. 
 
NO rapidly reacts with oxyhemoglobin to form NO3- and 
met-hemoglobin.  The resulting spectral changes have been 
used as the basis of a spectrophotometric assay of NO 
synthase (Knowles et al., 1990).  With dual wavelength 
measurement at 401 and 421 nm this method has a sensitivity 
of less than 20nM. 
 
Formation of NO2- + NO3-, the oxygenation products of NO 
can be measured by a variety of techniques.  One of them 
uses reduction of NO3- to NO2- by nitrate reductase or 
metallic catalysts followed by the colorimetric Griess 
reaction (Stuehr et al., 1989).   
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7. Inhibition of NO Synthase 
 
The study of NO synthesis in mammalian systems has been 
greatly facilitated by the identification of competitive 
inhibitors of NO synthase.  N-Monomethyl-L-arginine (L-NMMA) 
is one of the most commonly used.  L-NMMA has been shown to 
be a competitive inhibitor (competitive with L-arginine) of 
all the form of NOS so far examined, with an IC50 of ~7.4 µM 
for iNOS (Stuehr et al. 1989).  A range of arginine analogs 
has been found to inhibit NO synthases.  Like L-NMMA, these 
compounds are competitive inhibitors.   
 
Another way of inhibiting NO synthase in biological 
systems is to limit the supply of one of its substrates or 
cofactors.  This type of indirect inhibition has been 
demonstrated using inhibitors (N-acetyl-5-hydroxytryptamine) 
of tetrahydrobiopterin (BH4) synthesis.  Because of the 
turnover of BH4 in intact cells and tissues, inhibition of 
its synthesis eventually results in deletion of BH4 to 
concentrations that limit NO synthesis.   
 
NOS has been demonstrated to be subject to feedback 
inhibition by NO: two forms of NOS, brain constitutive nNOS 
and macrophage inducible iNOS were shown to be inhibited by 
NO either produced by the enzyme itself or generated from 
chemical NO donors (Stuehr and Griffith, 1992).  It is 
likely that this inhibition results form interaction with 
the heme of NO synthase.   
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8. Remaining Questions about the Peptide Transporters 
 
A number of issues regarding the peptide transporters 
still remain to be investigated.   
(1) Are there additional H+/peptide transporters other 
than PepT1 and PepT2? What is the functional relationship, 
if any, between these transporters?   
(2) Is the H+/peptide cotransporter system is expressed 
in the plasma membrane of mammalian tissues other than the 
intestine and kidney?   
 
Northern blot analysis reveals the presence of mRNA 
transcripts that hybridize to the PepT1 cDNA probe in 
liver, brain, and pancreas.  However, no information is 
available on H+-couple peptide transport in these organs, 
whether the mRNA transcripts code for peptide transporters 
or for different transporters with homology to the peptide 
transporters remains to been investigated. 
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Chapter III 
 
Materials and Methods 
 
 1. Materials  
 
Male Sprague-Dawley rats weighing 200-250 g (Hilltop 
Labs.  Scottsdale, PA) were used as a source for alveolar 
macrophages (AM) throughout this studies.  E.Coli 
lipopolysaccharide (LPS), arginine (Arg), Arg-Sar, Arg-Gly, 
Arg-Lys, Arg-Gly-Asp, cephradine, and cephalexin were 
obtained from Sigma Co (St. Louis, MO).  Fluorescein 
isothiocynate (FITC)-labeled lysine (Lys*) and lysine-
containing peptides (β-Ala-Lys*, Arg-Lys*, and Gly-Sar-Lys*) 
were purchased from Genemed Synthesis, Inc (San Francisco, 
CA).  In order to probe the presence of pepT1-like 
transporter on AM, two peptide segments (Peptide I and 
Peptide II) corresponding to P457-471 (PGHRHTLLVWGPNLY) and 
P480-494 (QKPEKGENGIRFVST) of the extracellular domain of 
rat pepT1 (Miyamoto, 1996) were synthesized and their anti-
rabbit anti-sera [anti-p457-471 antiserum (antiserum I) and 
anti-p480-494 antiserum (antiserum II)] were developed 
commercially by Genemed Synthesis, Inc.  Peptides I and II 
represent two sections of the extracellular domain that 
show the highest degree of amino acid sequence homologous 
among rat, rabbit, and human pepT1.  Peptide II exhibits 
relatively higher hydrophilicity than Peptide I due to the 
presence of more charged amino acid residues (K, lysine; R, 
arginine; E glutamate).  Purified iNOs was obtained from 
CalbioChem (San Francisco, CA). Rat pepT1 protein was 
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kindly received from Dr. You-jun Fei (Department of 
Biochemistry, University of Georgia) as a gift.  All other 
reagents were purchased from Sigma Co. (St. Louis, MO). 
 
2. Methods 
 
2.1. Plasma Sample Preparation  
 
Male Sprague-Dawley rats (~ 250 g) were anesthetized 
with sodium pentobarbital (0.2 g/kg body weight).  seven ml 
of blood was collected from the abdominal aorta and kept in 
the heparinized ice-cold tubes. The blood samples were 
spiked with 1 mM Arg-Sar as an internal standard for 
subsequent HPLC analysis, centrifuged at 1500 x g at 4 0C 
for 10 min, and the plasma samples were collected.  Two and 
half ml of plasma were taken and boiled for 15 min 
(deproteinization).  The treated plasma was centrifuged at 
2000 x g at 40C for 30 min.  
 
The supernatant was loaded on to a C18 cartridge (Vac 
20, Waters) and the column was eluted with 30ml of 0.1% TFA 
in methanol/water (95:1, pH2.4), then 30 ml of water 
containing 30% methanol (pH 2.4), and 10 ml of deionized 
water (pH 8).  The third fraction was collected and 
lyophilized.  The freeze-dried fraction was re-dissolved in 
250 ul water.  50 ul of aliquots were stored at –800C until 
it was analyzed for ACPs measurement. 
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2.2. Bronchoalveolar Lavage Fluid Sample Preparation 
 
The bronchoalveolar lavage fluids were obtained by 
pulmonary lavage.  Briefly, rats were lavaged with 2 ml of 
the phosphate buffered medium as described above. The 
recovered BAL fluid (~ 1 ml) for each rat was centrifuged 
at 500 x g for 5 minutes.  The supernatant for each sample 
was mixed with an equal volume of 6% sulfosalicylic acid.  
The treated fluid was centrifuged at 2000 x g at 4 0C for 20 
min, and loaded into a C18 cartridge (Vac 6, Waters).  The 
column was eluted in succession with 15 ml of water-
saturated ethyl acetate (pH 2.4), 15 ml of 30% methanol in 
water (pH 2.4), and 3 ml of deionized water (pH 8.0).  The 
last fraction was collected and lyophilized.  The freeze-
dried fraction was re-dissolved in 100 µl water.  Aliqots of 
20 µl samples were stored at –800C until time for analysis.  
 
 
2.3. Separation of Arginine and Arginine-Containing 
Peptides by HPLC 
 
The separation of arginine and arginine-containing 
peptides was achieved by using high performance liquid 
chromatography (HLPC).  The HPLC system consisted a Waters 
600E system controller, Waters WISP 701B autosampler, 
Waters 486 tunable absorbance detector, and Waters 746 data 
module (Waters Corp., Milford, MA).  The HPLC separation 
method was developed by using a C18 reversed-phase column 
(Keystone Scientific, 150 x 4.6 mm, 3 um) and a mobile 
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phase consisting of 0.1% trifluoroacetic acid (TFA, pH 2.4) 
in water as solvent A and 0.1% TFA in CH3CN as solvent B.  
The flow rate was 1 ml/min with 90% of solvent A and 10% 
solvent B.  Elutes were detected by UV detection at 215 nm.  
Commercially available L-arginine, Arg-Gly, and Arg-Gly-Asp 
were chosen as standards and Arg-Sar as an internal 
standard.   
 
2.4. Quantitative Determination of Arginine and Arginine-
Containing Peptides 
 
Standard samples for each compound of analysis was 
prepared by spiking known concentrations of the compound in 
the appropriate fluid, followed by the extraction 
procedures described above.  Following HPLC analysis, a 
standard curve was generated by plotting the peak area 
ratio of compound/internal standard against the 
concentration ratio of the compound /internal standard.  
Linear regression analysis was made, and the standard curve 
was used to determine the concentration of the compound. 
 
2.5. Accuracy and Precision 
 
 Plasma samples were repeatedly measured by HPLC 
according to the method described above at different times 
within a day, or different days.  The samples were kept in 
ice (within a day) or frozen at –80 0C (different days). 
Precision values of the within-day (interassay) and 
between-day (intraassay) were determined in six replicates 
at each concentration of 0.2, 1.0, and 2.0 ug/ul for Arg; 
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0.05, 0.1, and 1.0 ug/ul for Arg-Gly; 0.01, 0.1, and 0.2 
ug/ul for Arg-Gly-Asp in plasma and bronchoalveolar lavage 
fluid.  The mean concentrations and the coefficients of 
variation were calculated.  The accuracy of the assay was 
determined by comparing the nominal concentrations with the 
corresponding concentrations via linear regression.   
 
2.6. Sample Recovery Experiment 
 
 A standard curve for the internal standard, Arg-Sar, 
was first generated by the plot of a series of Arg-Sar 
standard solutions (0.2, 0.5, 1.0, 1.5, and 2.0 mM) against 
the corresponded peak area.  Arg-Sar was added into 10 ml 
blood sample or 1 ml lavage fluid (20 uM final 
concentration).  The sample was then processed as described 
in 2.1. or 2.2.  The amount of Arg-Sar recovered from the 
plasma or lavage fluid was determined according to the 
method described in 2.4.  The recovery rate was calculated 
using following formula: 
(amount measured / amount added) X 100% 
 
20 uM of arginine and arginine-containing peptides 
were added into 10 ml blood or 1 ml lavage fluid, 
respectively.  10 ml blood and 1 ml lavage fluid without 
arginine and arginine-containing peptides addition were 
used as controls.  After following the same procedure as 
Arg-Sar described above, the recover ratios for Arg, Arg-
Gly, Arg-Gly-Asp were determined by using a similar method 
except for the subtraction of the corresponding amounts of 
Arg, Arg-Gly, Arg-Gly-Asp in the blood.  
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[(amount measured – amount in control) / amount added] X 
100% 
 
2.7. Arginine-Containing Peptides Uptake and Utilization by 
Alveolar Macrophages 
 
2.7.1. Isolation of Alveolar Macrophages 
 
Male Sprague-Dawley rats (~ 250 g) were anesthetized 
with sodium pentobarbital (0.2 g/kg body weight) and 
exsanguinated by cutting the renal artery. Alveolar 
macrophages were obtained by pulmonary lavage with a Ca2+, 
Mg2+-free phosphate-buffered medium (145 mM NaCl, 5mM KCl, 
1.9 mM NaH2PO4, 9.35 mM Na2HPO4, and 5.5 mM glucose, pH 7.4). 
Lavaged cells were centrifuged at a 500 x g for 5 minutes, 
washed, and resuspended in the same phosphate-buffered 
medium. Cell counts and purity was measured using an 
electronic cell counter equipped with a cell sizing 
attachment (Coulter Electronics, Hialeah, FL). 
 
2.7.2. Intracellular Fluorescence Uptake by Alveolar 
Macrophages 
 
Isolated AM were dispersed into 24 well culture plates 
at 106 cells/well and was incubated with 5 uM of FITC, Lys*, 
β-Ala-Lys*, Arg-Lys*, or Gly-Sar-Lys* with/without 100 uM 
inhibitors (lysine and cephradine) in Earle’s salt solution 
for 2 hours at final volume of 1 ml.  The uptake was 
terminated by discarding the supernatant and adding ice-
cold Earle’s balanced salt solution.  The cells, were 
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washed 4 times with ice-cold Earle’s salt solution and were 
sonicated (MSE sonicator, Fisher, Pittsburgh, PA) for 15 
minutes.  After a 5 minutes centrifugation, the supernatant 
was collected and measured for relative fluorescence 
intensity at λex = 494 nm, λem = 519 nm.  
 
2.7.3. Utilization of Arginine-Containing Peptides by 
Alveolar Macrophages for Nitric Oxide (NO) Production 
 
Isolated AM were cultured at 1x106 AM/ml in arginine-
free Earle’s salt solution containing 2mM of glutamine and 
5% of fetal bovine serum with/without LPS (1ug/ml)(Thomas 
et al. 1993).  200uM of arginine or arginine-containing 
peptides (Arg-Gly, Arg-Gly-Asp) were added and incubated at 
37oC for 24 hours.  The AM-conditioned media were collected.  
NO production was determined by measuring the accumulation 
of nitrite using Greiss assay (Smith, et al. 1975).   
 
2.7.4. Inhibitory Effects of Anti-Rat PepT1 Antiserums on 
NO Production in AM  
 
 The cells were co-incubated with different 
concentrations of two rabbit anti-rat PepT1 antiserums 
(I,II) and arginine-containing peptides.  The inhibitory 
effects of inhibitors or antiserums on NO production by 
LPS-activated alveolar macrophages were determined 
according to the procedure described above. 
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2.7.5. Lactate Dehydrogenase (LDH) Determination 
 
Cell viability was determined by measuring the lactate 
dehydrogenase (LDH) from release of AM into the 
extracellular medium in various AM incubation mixtures 
using an automated Cobas FARA II (Rosh, San Francisco, CA).  
LDH activity was monitored spectrophotometrically at 340 nm 
as it reductated pyruvate and oxidated coupled with the 
oxidation of NADH. 
 
2.8. Presence of Peptide Transporter in Alveolar 
Macrophages 
 
2.8.1. Sample Preparation 
 
Isolated AM were seeded and cultured with or without 
LPS (1 ug/ml) in Earle’s salt culture medium for 24 hours.  
Cells were collected, washed with ice-cold PBS buffer, and 
centrifuged.  AM were suspended in homogenizing buffer (20% 
glycerol, 0.1 M Tris·HCl, and 10 mM EDTA, pH 7.4) containing 
various protease inhibitors (1 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM benzamidine, and 100 
µg/ml aprotinin).  The cell suspension was homogenized with 
a glass tissue grinder and sonicated for 10 second on ice. 
Homogenates were then centrifuged at 5,000 x g for 10 min. 
and the pellet (the nuclear fraction) was discarded.  The 
supernatant fluid was centrifuged at 50,000 x g for 2 hours 
and resulting pellet (cell membrane fraction) was 
resuspended in homogenizing buffer.  Protein concentration 
of the membrane fraction was determined by Lowry’s assay.  
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50 ml aliquots of the membrane preparations were stored at 
–80 0C.  
 
2.8.2. Western Blot 
 
  A membrane fraction containing 80 ug protein was 
loaded on 7% of SDS-PAGE and then transferred to a 
nitrocellulose membrane.  The membrane was incubated for 1 
hour with polyclonal rabbit antibodies specific to rat 
PepT1.  After washing, the blot was incubated sequentially 
with secondary antibody labeled with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Pierce, 
Rockford, IL) and detected by enhanced chemiluminescence.  
The signal densities of the protein bands were measured 
using a Fluochem 8000 densitometer (Alpha Innotech Corp., 
Alexandria, VA). 
 
2.9. Substrate Specificity Studies 
 
2.9.1. Utilization of Arginine-Containing Peptides by iNOS 
in vitro for NO Production  
 
Arginine-containing peptides were incubated with iNOS 
and NO production measured using a modified method of 
Stuehr et al. (1992).  Briefly, 0.1mg of iNOS was incubated 
with 200 uM of arginine, arginine-containing peptides (Arg-
Gly, Arg-Gly-Asp), 4 uM of H4biopterin, 4 uM of FAD, 3mM of 
dithiothreitol (DTT), 2mM of NADPH, and 40 mM of Tris HCl 
buffer (pH 7.9 total volume of 1 ml).  NO production was 
determined by Greiss assay.  The production of NO by 
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arginine-containing peptides was compared with that by 
arginine. 
 
2.9.2. Enzyme Kinetic Studies of Arginine-Containing 
Peptides for NO Production 
 
 Arginine, and arginine-containing peptides including 
Arg-Gly and Arg-Gly-Asp at the concentration of 15, 20, 30, 
60, 120,180, 240uM were incubated with iNOS, and Km and 
Vmax were determined using the Michaelis-Menten equation.  
For inhibition studies, NG-monomethyl-L-arginine (L-NMMA) 
was added to the reaction mixtures at concentration of 0, 
1, 4, 8, 12, 16, 20, 24, and 28 uM.  The IC50 was calculated 
by using the Winnonlin Nonlinear Estimation Program 
(V03.0A).   
 
3. Statistical Analysis 
 
Data are presented as mean ± standard deviations of at 
lease six measurements from different animals in all 
experiments.  Statistical analysis was conducted using a 
one-way analysis of variance (ANOVA) with a Tukey multiple 
comparison procedure with significance set at p< 0.05.  
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Chapter IV 
Results and Discussion 
 
1. Separation of arginine and arginine-containing peptides 
by HPLC 
 
Arg-Gly and Arg-Gly-Asp are chosen as representative 
of the arginine-containing di-and tri-peptides.  Arg-Sar, 
which contains the N-monomethylglycine residue, is not 
found in biological samples.  Due to its structural 
similarity to ACPs, stable and resistant to peptidase 
degradation, Arg-Sar was chosen as internal standard for 
the HPLC quantitative assay.   
 
Chromatographs of base line separation of arginine 
(Arg, R), arginine-containing peptides (Arg-Gly, RG; Arg-
Gly-Asp, RGD), and internal standard (Arg-Sar, RS) were 
shown in Figure 4.  The retention time was 5.8 min (Arg), 
7.5 min (Arg-Gly), 12.6 min (Arg-Gly-Asp), and 16.8 min 
(Arg-Sar) in rat plasma, respectively.  The similar results 
were in rat BAL fluid (Figure 5). 
 
2. Standard Curves 
 
Standard curves were generated for arginine or 
arginine-containing peptides by plotting the peak area 
ratio of compound/internal standard against the 
concentration ratio of the compound /internal standard.  
The standard curves were obtained in the concentration 
range of 0.2 – 2.0 µg/µl for Arg, 0.05 – 1.0 µg/µl for Arg-
  Chapter IV Results and Discussion 
 31 
 
Gly, and 0.01 – 0.2 µg/µl.  The limit of quantitation (LOQ) 
was set at 0.2 µg/µl for Arg, 0.05 µg/µl for Arg-Gly, and 
0.01 µg/µl for Arg-Gly-Asp in both plasma and BAL fluid. 
 
3. Sample Recovery Experiment 
 
six samples of plasma and lavage fluid, with or 
without the addition of standard arginine and arginine-
containing peptides, were processed and analyzed as 
described in the method section.  Recovery rates of Arg, 
and arginine-containing peptides from rat plasma and BAL 
fluid were calculated and shown in table I.  
 
Table I shows the % recovery of arginine and the 
peptides in plasma and in BAL fluid samples for the 
developed HPLC method.  The sample preparation procedure 
resulted in a ~15 % loss of added concentration in plasma 
and less then 10 % loss of concentrations in BAL fluid.  
These results are within acceptable ranges for biological 
samples.  In addition, the recovery rate for all testing 
compounds is about the same, suggesting that this method 
should be very consistent for the analysis of the 
individual and relative quantities of arginine and the 
arginine-containing peptides.   
 
4. Accuracy and Precision 
 
The accuracy and precision for quantitative assay of 
Arg and ACPs from plasma and BAL fluid were processed as 
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described in method section and the results were shown in 
Table II-IV.   
 
The within-day precision expressed as the coefficients 
of variation (% C.V.).  As shown in these tables, in 
plasam, the values for Arg ranged from 7.9 to 11.8%.  For 
Arg-Gly, the value ranged from 7.9 to 13.  For Arg-Gly-Asp, 
the value ranged from 4.3 to 14.1. 
 
The accuracy of the assay in plasma varied in the 
range from 99.4 to 105.2% for Arg; from 102.5 to 104 for 
Arg-Gly; and from 101.3 to 102.2% for Arg-Gly-Asp. 
 
The similar CV % and accuracy results were obtained in 
BAL fluids.  CV% value for Arg ranged from 8.3 to 11.4%; 
for Arg-Gly from 5.2 to 11.3%; for Arg-Gly-Asp from 5.7 to 
11.6 (table not shown).  For accuracy, Arg from 99.1 to 
100.8%; Arg-Gly from 98.9 to 100.4%; and Arg-Gly-Asp from 
100.1 to 101.3%. 
 
According to FDA “Specific Recommendation for Method 
Validation”, the acceptance criteria are not more than 15% 
CV for precision and not more than 15% deviation for the 
nominal value for accuracy.  The method for quantitative 
assay for Arg and ACPs reached the FDA requirement, 
suggesting the HPLC method for quantitative assay for Arg 
and ACPs are reliable. 
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5. Determination of Arginine and Arginine-Containing 
Peptides in Plasma and Bronchoalveolar Lavage Fluid. 
 
 The concentrations of arginine and arginine-containing 
peptides in plasma and bronchoalveolar lavage fluid are 
shown in table V.  The concentration of arginine in rat 
plasma was 81 uM, which is similar to that previously 
reported by Barbul (1990).  The plasma concentration of 
Arg-Gly, and Arg-Gly-Asp was 19.7 uM and 8.8 um, 
respectively.  These results demonstrate for the first time 
the presence of arginine-containing peptides in rat plasma. 
 
Considering the possible different combinations of 
arginine and other amino acids, the total concentration of 
arginine-containing peptides in plasma is high.  This 
suggests that such as a large quantity of arginine-
containing peptides may be utilized by different tissues.  
Notably, the similarly high concentration of arginine-
containing peptides in bronchoalveolar lavage fluid 
suggests that these small peptides may also be directly 
utilized by the lung tissues.   
 
6. Intracellular Fluorescence Uptake by AM 
 
To test the whether the small peptides can be directly 
utilized by the lung, the uptake of fluorescently 
conjugated peptides by AM was compared to that of 
fluorescently conjugated amino acid and fluorescent probe 
(FITC) only.  As shown in Fig 3, the uptake of FITC by AM 
was minimal.  In contrast FITC-labeled Lys (Lys*) and small 
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peptides (β-Ala-Lys*, Arg-Lys*, and Gly-Sar-Lys*) showed 
enhanced intracellular accumulation, suggesting active 
transport-mediated uptake of the compounds.  The uptake of 
Lys* by AM was completely blocked by non-labeled lysine but 
was not inhibited by cephradine, a reported substrate for 
PepT1 transporter.  The uptake of the small peptides was 
consistently inhibited by cephradine but not by lysine.  
These results suggested that the small peptides were 
transported through a membrane transporter that is 
different from the lysine transporter, and were 
internalized by AM without prior degradation.  
 
7. Utilization of Arginine-Containing Peptides by Alveolar 
Macrophages for Nitric Oxide (NO) Production 
 
 To determine if AM can directly utilize the small 
peptides for NO production, NO production of these peptides 
in LPS-activated AM was measured and compared with that by 
arginine.  Table VI shows the production of NO by non-
stimulated and LPS-stimulated AM in the presence of 200 µM 
arginine or arginine-containing di- and tri-peptides.  
While both arginine and the small peptides were utilized by 
AM to produce NO, the production of nitrite through the 
peptides was consistently higher (~ 2-fold) than that of 
the arginine system, in LPS-primed cells.   
 
Figure 7 shows the effect of various inhibitors of membrane 
transport on NO production in LPS-stimulated AM.   
Lysophosphatidylcholine (LPC) has been identified as a 
potent inhibitor of CAT-2B-mediated amino acid transport.  
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Our results showed that LPC at 5 µM, significantly inhibited 
NO production through arginine but had little or no effect 
on AM production of NO through arginine-containing 
peptides.  In addition, lysine (1 mM) markedly inhibited NO 
generation through the arginine system, but failed to block 
NO production generated through Arg-Gly or Arg-Gly-Asp.   
Interestingly, lysine also blocked AM production of NO 
through the use of Arg-Lys as a substrate.  This was not 
expected, but presumably due to the fact that both the 
arginine and lysine moieties are cationic, thus allowing 
this small peptide to be transported by both the amino acid 
and peptide transporters.  Figure 2 further shows that the 
PepT1 inhibitors, cephalexin and cephradine, selectively 
inhibited NO production through the arginine-containing 
peptides, but had little effect on the arginine system.  
 
The above results clearly show that LPS-induced iNOS 
activity in AM for NO synthesis is largely dependent upon 
the transport or uptake of the substrate(s).  While 
arginine is transported through CAT-2B, the arginine-
containing peptides are internalized through a peptide 
transporter. This finding is different from that of an 
earlier study on chicken macrophages, which suggested that 
arginine-containing dipeptides were hydrolyzed to produce 
arginine before cellular uptake (Su and Austic, 1998).  The 
fact that these peptides resulted in increased production 
of NO, 2-fold to that produced through arginine, suggests 
that these small peptides are more efficiently taken up by 
the cells or they may serve as direct and better substrates 
for iNOS. 
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8. Inhibitory Effects of Anti-Rat PepT1 Antiserums on 
Utilization of Arginine-Containing Peptides for NO 
Production in AM  
 
A number of transporters including PepT1 and PepT2 
have been identified for di- and tri-peptide transport (Fei 
et al., 1994; Saito et al., 1996).  It is reasonable to 
suggest that in various organ systems, where transport or 
absorption of small peptides is necessary, there are 
similar peptide transporters.  In the lung, it is already 
reported that peptide transporter(s) is present in Type II 
cells, the broncho epithelium, and the small vessel 
endothelium (Groneberg et al., 2001).  We hypothesize that 
a PepT1-like transporter is responsible for the uptake of 
arginine-containing di- and tri-peptides in AM.  For this 
reason, two peptide segments of the extracellular domain of 
rat pepT1 were chosen for antibody production.  These 
peptide segments represent regions of the extracellular 
domain that have the highest degree of amino acid sequence 
homologous among rat, rabbit, and human PepT1 proteins, 
which makes it possible that these regions may be involved 
in the binding of small peptides.  Figure 8 shows the 
effects of anti-pepT1 anti-serum I and anti-pepT1 anti-
serum II on NO production by LPS-stimulated AM using 
arginine or arginine-containing peptides as a substrate.  
Anti-serum I had no effect on NO synthesis in any of the 
systems.  But the production of NO was significantly 
blocked by anti-serum II.  Neither antibody affected the NO 
production using arginine as the substrate.  The inhibitory 
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effect of antipepT1 antiserum II on AM utilization of 
arginine-containing peptides for NO production was dose-
dependent (Figure 9).  In comparison, antiserum I in the 
same concentration range did not inhibit the production of 
NO by AM (Figure 10).  It is interesting to point out that 
the inhibitory effect of anti-serum II on Arg-lys is 
considerably weaker than its inhibition on other peptides.  
This again suggests that Arg-lys may be transported through 
both the peptide and the cationic amino acid transporters.  
 
Antiserum II is derived from the peptide segment of 
pepT1 that contains more charged amino acid residues than 
peptide I, the corresponding peptide segment for antiserum 
I.  This makes peptide II a more likely segment to be 
involved in the proton-coupled small peptide transport 
process.  The fact that antiserum II inhibits AM 
utilization of the arginine-containing peptides indicate 
that AM indeed exhibit a pepT1-like transporter, and that 
antiserum II was able to bind and inactivate the 
extracellular binding site of the transporter that is 
crucial to the peptide transport process.   
 
9. Lactate Dehydrogenase (LDH) Determination 
 
 The LDH level was determined in control groups 
(without LPS stimulation or any compounds added) and 
treatment groups (stimulated with LPS or compounds added).  
No statistically significant difference between the two 
groups was found, suggesting that no significant cytotoxic 
effects occurred during experiments.  
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10. Detection of PepT1-like Transporter Protein in Cell 
Membrane of AM 
 
Figure 11 shows the Western blotting analysis of the 
presence of a PepT1-like transporter protein in the cell 
membrane of AM.  In compared to the purified rat PepT1 
protein, a 120 kD band, was detected in the membrane 
fraction of both LPS-activated and non-activated AM, using 
antiserum II.  This protein band was not observed in 
antiserum I-treated membrane fractions, suggesting that the 
corresponding peptide I segment is probably not present in 
the peptide transporter in alveolar macrophages.  
 
Interestingly, when the amino acid sequences of 
peptide I (P457-471) and peptide II (P480-494) from rat 
pepT1 are compared to those of rat pepT2, there is only 13 
% homology for peptide I, but 50 % for peptide II.  This 
supports our data that peptide II is involved in the 
process of small peptide transport.  The density of the 
protein band from LPS-activated AM was significantly higher 
(by 2.3-folds) than that of the non-activated AM, 
suggesting that LPS, which is known to induce iNOS, also 
enhance AM uptake of small peptides through the pepT1-like 
transporter.  These results further confirm the presence of 
PepT1-like transporter in AM and suggest a role for AM in 
regulating lung peptide homeostasis.  
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11. Substrate Specificity Studies 
 
 Arginine-containing peptides were incubated with iNOS 
in vitro to investigate whether the small peptides can be 
used as direct substrates for iNOS in NO production.  The 
results show that these compounds can be used as direct 
substrates for NO production and that these peptides or 
amino acid produced a similar amount of NO at certain time 
(Fig 9, 10, 11).  Kinetic studies showed that Arginine and 
arginine-containing peptides shared similar Km and Vmax 
(Fig 12; Table IV), suggesting that the efficiency for NO 
production is similar among these compounds.  The NO 
production can be blocked by NG-monomethyl-L-arginine (L-
NMMA) with a similar IC50 value (Table VII).  This finding 
suggested that these compounds might share a similar active 
site of iNOS.   
 
This result appeared to be contradictory to the 
observation that arginine-containing peptides resulted in 
more NO production by AM than using arginine as a 
substrate.  One possible explanation is that the CAT-2B 
transporter, which transports cationic amino acids, may be 
blocked by biological compounds such as other amino acids, 
LPC, etc, whereas the PepT1-like transporter in the 
membrane of AM is more selective in transporting peptide 
molecules. 
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Figure 1.  Structure of PepT1 (Fei et al., 1994) and 
location of two chosen peptide segments for anti-PepT1 
antibody development. 
 
PepT1 protein has 12 transcellular domains.  Both N-
terminal and C-terminal locate intracellularly.  It has a 
big extracellular loop which is believed as a important 
part for its transport functioning.  Two peptide segments 
(peptide I and peptide II) were chosen from the loop for 
the development of anti-PepT1 antibody development. 
 
CO
       + + + 
Peptide I  (P457-471):  PGHRHTLLVWGPNLY 
    +    - +     -        + 
Peptide II (P480-494): QKPEKGENGIRFVST 
+
_ _++
++
P457-471 P480-494 
COOH 
NH2 
  Chapter IV Results and Discussion 
 41 
 
 
 
MGMSKSLSCFGYPLSIFFIVVNEFCERFSYYGMRALLILYFRNFIGWDDNL 
         1 
STVIYHTFVALCYLTPILGALIADAWLGKFKTIVWLSIVYTIGQAVTSLSSV 
2            3 
NELTDNNHDGTPDSLPVHVAVCMIGLLLIALGTGGIKPCVSAFGGDQFEEG 
              4 
QEKQRNRFFSIFYLAINAGSLLSTIITPMVRVQQCGIHVKQACYPLAFGIPAI 
5 
LMAVSLIVFIIGSGMYKKFKPQGNILSKVVKCICFAIKNRFRHRSKQFPKRA 
6 
HWLDWAKEKYDERLIAQIKMVTRVLFLYIPLPMFWALFDQQGSRWTLQA 
7 
TTMSGRIGILEIQPDQMQTVNTILIIILVPIMDAVVYPLIAKCGLNFTSLKKM 
8 
TIGMFLSAMAFVAAAILQVEIDKTLPVFPKANEVQIKVLNVGSENMIISLPG 
9 
QTVTLNQMSQTNEFMTFNEDTLTSINITSGSQVTMITPSLEPGHRHTLLV 
 
WGPNLYRVVNDGLTQKPEKGENGIRFVSTYSQPINVTMSGKVYEHIASY 
 
NASEYQFFTSGVKGFTVSSAGISEQCDFESPYLEFGSAYTYLITSQATGCPQ 
 
VTEFEDIPPNTMNMAWQIPQYFLITSGEVVFSITGLEFSYSQAPSNMKSVL 
10 
QAGWLLTVAVGNIIVLIVAGAGQINKQWAEYILFAALLLVVCVIFAIMARF 
11       12 
YTYVNPAEIEAQFEEDEKKKNPEKNDLYPSLAPVSQTQ 
 
 
Figure 2.  Amino acid sequence of PepT1 in rat intestinal 
epithelial cell (Miyamoto et al., 1996).   
 
The numbers of 1 - 12 represent 12 transcellular 
domains.  The extracellular loop is shown as black color 
and the peptide I and II is shown as red color. 
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Peptide I segment  
 
Rat:  PGHRHTLLVWGPNLY 
Rabbit : A**Q***A*****N* 
Human: Q**Q***A*****H* 
 
Peptide II segment 
 
Rat:  QKPEKGENGIRFVST 
Rabbit : **SD*********N* 
Human: *************N* 
 
Figure 3.  Comparison of amino acid sequence identity of 
peptide I and peptide II segments chosen as anti-pepT1 
antibody development in different species. 
 
Peptide I segment shares 73% of amino acid identities 
among rat, rabbit, and human, respectively.  In comparison 
to peptide I, peptide II not only shares higher identity 
(80%) between rat and rabbit but also shares the highest 
identity between rat and human (93%).   
* represents the identical amino acid. 
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Figure 4. Chromatogram of HPLC Separation of Arginine and 
Arginine-Containing Peptides in Plasma Sample.  The elutes 
were Arg (R), Arg-Gly (RG), Arg-Gly-Asp (RGD), and Arg-Sar 
(RS).   
 
 
 
 
 
 
 
 
 
R
RG 
RGD 
RS 
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Figure 5. Chromatogram of HPLC Separation of Arginine 
and Arginine-Containing Peptides in Bronchoalveolar lavage 
fluid Sample.  The elutes were Arg (R), Arg-Gly (RG), Arg-
Gly-Asp (RGD), and Arg-Sar (RS). 
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Table I. Recovery Rate of Arginine and Arginine-
Containing Peptides from Blood and Bronchoalveolar 
Lavage Fluid 
 
 
 
Recovery rate (%) 
 
Blood Lavage Fluid 
Arg 83.74 ± 1.24 90.32 ± 2.34 
Arg-Gly 86.65 ± 2.34 91.46 ± 1.86 
Arg-Gly-Asp 87.32 ± 2.06 90.47 ± 2.41 
N=5, data are expressed as Mean ± standard deviation 
(SD). 
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Table II. Evaluation of accuracy and precision for the assay 
of arginine in plasma sample 
 
 
 
Arginine (µg/µl)  
0.2 1.0 2.0 
Within-day 
Calculated 
 
 
 
 
 
Average ± S.D. 
C.V. (%) 
Accuracy 
 
Between-day 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Average ± S.D. 
C.V. (%) 
 
0.20 
0.22 
0.185 
0.171 
0.20 
0.21 
0.20 ± 0.02 
11.8 
101.1 
 
 
0.23 
0.197 
0.188 
0.25 
0.21 
0.22 
0.22 ± 0.02 
10.5 
 
1.08 
0.99 
1.16 
1.10 
0.96 
0.94 
1.04 ± 0.09 
8.4 
105.2 
 
 
0.87 
1.03 
1.12 
0.99 
0.97 
1.05 
1.00 ± 0.08 
8.4 
 
2.13 
2.00 
1.89 
1.96 
2.21 
1.78 
2.00 ± 0.16 
7.9  
99.4 
 
 
2.16 
2.04 
1.97 
1.85 
2.00 
2.07 
2.01 ± 0.10 
5.2 
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Table III. Evaluation of accuracy and precision for the assay 
of Arg-Gly in plasma sample 
 
 
 
Arg-Gly (µg/µl)  
0.05 0.1 1.0 
Within-day 
Calculated 
 
 
 
 
 
Average ± S.D. 
C.V. (%) 
Accuracy 
 
Between-day 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Average ± S.D. 
C.V. (%) 
 
0.05 
0.046 
0.060 
0.061 
0.063 
0.05 
0.055 ± 0.01 
13.0 
103 
 
 
0.047 
0.05 
0.064 
0.046 
0.052 
0.061 
0.05 ± 0.01 
14.0 
 
0.13 
0.12 
0.09 
0.11 
0.12 
0.118 
0.11 ± 0.01 
11.9 
102.5 
 
 
0.086 
0.09 
0.12 
0.11 
0.10 
0.97 
0.10 ± 0.01 
12.6 
 
0.98 
1.07 
1.03 
0.89 
1.12 
1.06 
1.02 ± 0.08 
7.9 
104 
 
 
0.98 
1.05 
1.11 
1.00 
0.99 
1.07 
1.03 ± 0.05 
5.0 
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Table IV. Evaluation of accuracy and precision for the assay 
of Arg-Gly-Asp in plasma sample 
 
Arg-Gly-Asp (µg/µl)  
0.01 0.1 0.2 
Within-day 
Calculated 
 
 
 
 
 
Average ± S.D. 
C.V. (%) 
Accuracy 
 
Between-day 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Average ± S.D. 
C.V. (%) 
 
0.01 
0.012 
0.013 
0.01 
0.009 
0.01 
0.01 ± 0.01 
14.1 
101.3 
 
 
0.047 
0.05 
0.064 
0.046 
0.052 
0.061 
0.05 ± 0.01 
14.0 
 
0.09 
0.12 
0.113 
0.09 
0.12 
0.118 
0.11 ± 0.01 
13.4 
102.2 
 
 
0.11 
0.12 
0.09 
0.08 
0.10 
0.09 
0.10 ± 0.02 
15.0 
 
0.21 
0.20 
0.196 
0.206 
0.189 
0.19 
0.20 ± 0.01 
4.3 
101.4 
 
 
0.19 
0.23 
0.18 
0.20 
0.19 
0.18 
0.20 ± 0.02 
9.6 
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Table V. Concentrations of Arginine and Arginine-
Containing Peptides in rat Plasma and Bronchoalveolar 
Lavage Fluid. 
 
 
 
Concentration (uM) 
 
Blood BAL Fluid 
Arg 81.45 ± 3.28 82.61 ± 4.16 
Arg-Gly 19.65 ± 2.41 11.37 ± 2.46 
Arg-Gly-Asp 8.77 ± 1.03 7.62 ± 1.61 
N=6, data are expressed as Mean ± standard deviation 
(SD). 
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Figure 6. Transporter-mediated uptake of 5 µM FITC-
labeled lysine (Lys*) and small peptides (Arg-Lys*, 
β-Ala-Lys*, Gly-Sar-Lys*) by alveolar macrophages 
(106 Cells).  Lys (1 mM) and cephradine (1mM) was 
used as inhibitors for CAT-2B and PepT1 transporters, 
respectively.  * Significant difference from control 
at P < 0.05, n = 6. 
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Table VI. Production of NO by non-stimulated and LPS-
stimulated AM in the presence of arginine and arginine-
containing peptides 
 
 
 
Nitrite (µM) 
 
 
 
 
Substrate -LPS 
 
+LPS 
 
      Cells only 1.4 ± 0.2 
 
2.5 ± 0.3 
       Arg 
 
2.1 ± 0.4 21.5 ± 3.5 
       Arg-Lys 
 
7.2 ± 1.3 39.2 ± 5.1* 
       Arg-Gly 
 
5.1 ± 0.3 41.9 ± 3.6* 
       Arg-Gly-Asp 
 
3.7 ± 1.0 38.4 ± 2.1* 
 
 
At equal molar concentration (200uM) of Arg and ACPs, NO 
production from 106 AM with/without LPS stimulation was 
measured following 24-hour incubation and expressed as 
nitrite (uM).  Each value represents the mean ± SD of six 
separation experiments.  
* indicates significant difference from AM + Arg, p < 0.05 
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Figure 7.  Inhibitory effects of CAT and PepT1 transporter 
inhibitors on NO production by LPS-stimulated AM. 1mM of 
Lys, cephradine, and cephalexin; 5uM of LPC were used as 
inhibitors. * indicates significant difference from control 
at P < 0.05; n = 6. 
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Figure 8. Effects of anti-PepT1 antiserum I (1:10) and 
anti-PepT1 antiserum II (1:10) on AM production of NO 
using arginine and arginine-containing peptides as 
substrates.  
* indicates significant difference from the control 
(Arg). P < 0.05, n = 6. 
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Figure 9. The dose-dependent effects of anti-PepT1 
antiserum II on NO production by LPS-stimulated AM using 
arginine or arginine-containing peptides as the substrates.   
 
The antiserum dilutions were 1:100, 1:20, 1:10, 1:2. 
Antiserum II significantly block the NO production by Arg-
Lys, Arg-Gly-Asp in a dose dependent manner. N=6, P < 0.05. 
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Figure 10. The dose-dependent effects of anti-PepT1 
antiserum I on NO production by LPS-stimulated AM using 
arginine or ACPs as the substrates.  The antiserum 
dilutions were 1:100, 1:20, 1:10, 1:2. N=6, P < 0.05. 
Unlike to the antiserum II, no dose-dependent effects of 
the antiserum I on NO production by LPS-stimulated AM were 
observed.  
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Figure 11. Western Blot of PepT1-like Transporter on the 
membrane fraction of AM. 
A 120 kD bands were detected in membrane fraction of 
both LPS-stimulated and non-stimulated AM using anti-
PepT1 antiserum II. Western Blot of AM membrane proteins 
using anti-p480-494 antiserum (antiserum II).  The signal 
densities of corresponding bands were measured. 
A: Molecular weight marker;  B: Preimmune serum;  C: 
PepT1 standard protein;  D: LPS-stimulated AM;  E: Non-
stimulated AM.  
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Figure 12. Michaelis-Menten Saturation Curve of Arginine.  
n = 5.  The Kinetics was carried out by incubation of 0.1 
mg iNOS with arginine as substrates at concentration of 15, 
20, 30, 60, 120, 180, and 240 µM for 4 min.  The initial 
rates of NO synthesis were measured spectrophotometrically 
using the Greiss assay. 
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Figure 13. Michaelis-Menten Saturation Curve of Arg-Gly.  
n = 6.  The Kinetics was carried out by incubation of 0.1 
mg iNOS with Arg-Gly as substrates at concentration of 15, 
20, 30, 60, 120, 180, and 240 µM for 4 min.  The initial 
rates of NO synthesis were measured spectrophotometrically 
using the Greiss assay. 
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Figure 14. Michaelis-Menten Saturation Curve of Arg-Gly-
Asp.  
n = 5.  The Kinetics was carried out by incubation of 0.1 
mg iNOS with Arg-Gly-Asp as substrates at concentration of 
15, 20, 30, 60, 120, 180, and 240 µM for 4 min.  The 
initial rates of NO synthesis were measured 
spectrophotometrically using the Greiss assay. 
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Figure 15. Lineweaver-Burk plots for iNOS activity using 
Arg, Arg-Gly, and Arg-Gly-Asp as substrate (n=5).   
 
The enzyme reactions were carried out by incubation 
0.1 mg iNOS with arginine or arginine-containing peptides 
at concentrations of 15, 20, 30, 60, 120, 180, and 240 µM 
for 4 min. The initial rates of NO synthesis were measured 
spectrophotometrically using the Greiss assay. 
 
 
 
 
1/S
-0.04 -0.02 0.00 0.02 0.04 0.06 0.08
1/
V
o 
0.0
0.2
0.4
0.6
0.8
1.0
Arg
Arg-Gly
Arg-Gly-Asp
  Chapter IV Results and Discussion 
 61 
 
 
 
 
 
Table VII.  Km, Vmax, and IC50 values for the enzyme kinetics 
of iNOS using Arg, Arg-Gly, and Arg-Gly-Asp as substrates 
and L-NMMA as a competitive NO inhibitor. 
 
 
Substrate Km  
(µM) 
Vmax 
(µmol/min/mg protein) 
IC50 (L-NMMA) 
(µM) 
Arg 59.3 ± 2.1 6.6 ± 0.7 14.2 ± 1.1 
Arg-Gly 56.0 ± 1.8 8.4 ± 1.2 12.8 ± 0.8 
Arg-Gly-Asp 60.1 ± 2.2 6.8 ± 1.3 14.0 ± 0.6 
Each value represents the mean ± SD of six separation 
experiments. 
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Chapter V 
Summary and Conclusion 
 
A HPLC method to analyze arginine and arginine-
containing peptides from blood and bronchoalveolar lavage 
fluid has been established.  The accuracy and precision of 
assay is within 15% deviation and 15% C.V., respectively, 
which reach the FDA requirement for analytical method 
validation guide.  The limit of quantitation (LOQ) was in 
nano-range without derivatization, 0.2 µg/µl for Arginine, 
0.05 µg/µl for Arg-Gly, and 0.01 µg/µl for Arg-Gly-Asp in 
both plasma and BAL fluid. So the method is simple, 
accuracy and reliable. 
 
This project also demonstrates that arginine-
containing di- and tri-peptides are direct substrates to 
the inducible nitric oxide synthase.  Arginine-containing 
peptides such as Arg-Gly and Arg-Gly-Asp, which are present 
in significant concentrations in plasma and the lungs, can 
be readily internalized through a peptide transport process 
and utilized for NO synthesis by a variety of cell types.  
This notion is in agreement with several reports that many 
di- and tri-peptides in plasma are directly absorbed by 
various organs without hydrolytic degradation (Lochs et 
al., 1988; Fei et al., 1994).  In the pulmonary system, 
where NO production on one hand protects the lung from 
bacteria infection (Boockvar et al., 1994) and on the other 
hand exacerbates inflammatory lung injury, AM are shown to 
exhibit PepT1-like transporter and produce high levels of 
NO by directly using arginine-containing peptides as 
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substrates. This study suggests a plausible mechanism 
through which a significant portion of the NO production by 
AM may be generated.  
 
The transport and utilization of arginine-containing 
peptides by AM may have a broader implication on the 
regulatory role of peptide transporters in various 
biological systems.  Studies have shown that renal-impaired 
patients may develop hypertension due to reduced production 
of NO by endothelial cells.  The reason for the reduction 
of NO synthesis has been attributed to a blockage of 
arginine transport through the CAT-2B transporter by 
compounds such as LPC, a natural CAT-2B inhibitor (Kikuta 
et al., 1998; Caivano, 1998).  Our studies showed that LPC 
indeed blocked AM production of NO through arginine uptake 
but had no effect on the cellular uptake and utilization of 
the arginine-containing peptides.  This suggests that 
arginine-containing peptides, which are internalized 
through a peptide transporter, may be considered as an 
alternative source of substrates for NO synthesis.  
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